Entry into a Material Definitive Agreement. Sorrento Therapeutics has recently disclosed positive results in anti-COVID allogeneic adipose stem cells research. ACEA Therapeutics is a clinical-stage, fully-integrated, pharmaceutical company committed to developing and delivering innovative treatments to improve the lives of patients with life-threatening diseases. I te m 9.01. There are 1.5 million lupus cases in the US and 5 million worldwide. What happenedShares of Sorrento Therapeutics (NASDAQ: SRNE) were skyrocketing 38.5% as of 12:24 p.m. EST on Wednesday. On May 21, 2020, Sorrento Therapeutics, Inc. issued a press release announcing that it has entered into a binding term sheet with ACEA Therapeutics, Inc. (“ACEA”) for an exclusive license to ACEA’s Abivertinib across all indications for all territories outside of China. The non-small cell lung … The same day, a filing with the U.S. Securities and Exchange Commission (though, oddly, not a company press release) announced the acquisition of ACEA Therapeutics. F … ACEA Therapeutics General Information Description. Personalized Stem Cells, Inc. announces first patients treated in COVID-19 FDA approved stem cell clinical trial licensed to Sorrento Therapeutics. Here is how ACEA … The company focuses on innovative oncology drugs and developing small molecules for the treatment of cancer and autoimmune diseases, enabling doctors to improve the lives of patients with chronic and life-threatening diseases. Developer of oncology drugs intended to better fight chronic and life-threatening diseases. Sorrento would gain ACEA's Lupus program which is completing a phase 1b trial in Dallas in December 2020. On May 21, 2020, Sorrento reached an exclusive license agreement with ACEA Therapeutics for Abivertinib "across all indications for all territories outside of China." On July 13, 2020, Sorrento Therapeutics, Inc. (the "Company") entered into a License Agreement (the "License Agreement") with ACEA Therapeutics, Inc. ("ACEA"). The company acquired rights outside of China to the candidate for non-small cell lung cancer from ACEA Therapeutics. SAN DIEGO, May 21, 2020 -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) and ACEA Therapeutics, Inc. (“ACEA”) have entered into a binding term sheet for an exclusive license to ACEA’s Abivertinib across all indications for all territories outside of China.The final terms of the license will be set forth in a definitive agreement to be entered into between the parties. Item 1.01.